Neurocrine Biosciences (NBIX) Finished Goods (2017 - 2025)

Neurocrine Biosciences (NBIX) has reported Finished Goods for 9 consecutive years, with $13.6 million the latest figure, recorded in Q1 2025.

• For the quarter ending Q1 2025, Finished Goods rose 81.33% year-over-year to $13.6 million; the trailing twelve-month figure through Mar 2025 stood at $13.6 million (up 81.33% YoY), and the FY2024 full-year result was $12.8 million, up 4.07% from the prior year.
• Finished Goods climbed to $13.6 million in Q1 2025 per NBIX's latest filing, from $12.8 million in the prior quarter.
• Across five years, Finished Goods topped out at $17.5 million in Q4 2022 and bottomed at $7.5 million in Q1 2024.
• Historically, Finished Goods has averaged $12.7 million across 5 years, with a median of $12.5 million in 2023.
• The sharpest annual moves came in 2023 and 2025: Finished Goods dropped 29.71% in 2023, then jumped 81.33% in 2025.
• Over 5 years, Finished Goods stood at $15.7 million in 2021, then gained by 11.46% to $17.5 million in 2022, then decreased by 29.71% to $12.3 million in 2023, then increased by 4.07% to $12.8 million in 2024, then grew by 6.25% to $13.6 million in 2025.
• According to Business Quant data, Finished Goods over the past three periods registered $13.6 million, $12.8 million, and $11.5 million for Q1 2025, Q4 2024, and Q3 2024 respectively.